UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
| ☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2021 or
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _______________ to _______________.
Commission file number 001-08789
American Shared Hospital Services
(Exact name of registrant as specified in its charter)
|
California |
94-2918118 |
|
(State or other jurisdiction of
|
(IRS Employer
|
|
Two Embarcadero Center, |
Suite 410 |
San Francisco, |
California |
94111 |
|
(Address of principal executive offices) |
(Zip code) |
|||
(415) 788-5300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
American Shared Hospital Services Common Stock, No Par Value |
AMS |
NYSEAMER |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer ☐ | Accelerated Filer ☐ | Non-Accelerated Filer ☒ | Smaller reporting company ☒ |
| Emerging Growth Company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 9, 2021, there were outstanding 5,868,000 shares of the registrant’s common stock.
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
AMERICAN SHARED HOSPITAL SERVICES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
ASSETS |
September 30, 2021 |
December 31, 2020 |
||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | 7,050,000 | $ | 3,961,000 | ||||
|
Restricted cash |
118,000 | 364,000 | ||||||
|
Accounts receivable, net of allowance for doubtful accounts of $100,000 at September 30, 2021 and $100,000 at December 31, 2020 |
4,120,000 | 4,303,000 | ||||||
|
Other receivables |
671,000 | 272,000 | ||||||
|
Prepaid expenses and other current assets |
1,832,000 | 1,950,000 | ||||||
|
Total current assets |
13,791,000 | 10,850,000 | ||||||
|
Property and equipment: |
||||||||
|
Medical equipment and facilities |
72,175,000 | 75,657,000 | ||||||
|
Office equipment |
606,000 | 330,000 | ||||||
|
Construction in progress |
86,000 | 170,000 | ||||||
| 72,867,000 | 76,157,000 | |||||||
|
Accumulated depreciation and amortization |
(44,605,000 | ) | (45,739,000 | ) | ||||
|
Net property and equipment |
28,262,000 | 30,418,000 | ||||||
|
Land |
19,000 | 19,000 | ||||||
|
Goodwill |
1,265,000 | 1,265,000 | ||||||
|
Right of use assets |
660,000 | 886,000 | ||||||
|
Intangible asset |
78,000 | 78,000 | ||||||
|
Other assets |
72,000 | 137,000 | ||||||
|
Total assets |
$ | 44,147,000 | $ | 43,653,000 | ||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
September 30, 2021 |
December 31, 2020 |
||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | 277,000 | $ | 683,000 | ||||
|
Employee compensation and benefits |
426,000 | 405,000 | ||||||
|
Other accrued liabilities |
1,720,000 | 2,045,000 | ||||||
|
Asset retirement obligations |
652,000 | 1,270,000 | ||||||
|
Income taxes payable |
115,000 | 373,000 | ||||||
|
Working capital payment due |
- | 197,000 | ||||||
|
Current portion of lease liabilities |
311,000 | 305,000 | ||||||
|
Current portion of long-term debt, net |
1,081,000 | 1,157,000 | ||||||
|
Current portion of finance leases |
- | 5,945,000 | ||||||
|
Total current liabilities |
4,582,000 | 12,380,000 | ||||||
|
Long-term lease liabilities, less current portion |
349,000 | 581,000 | ||||||
|
Long-term debt, net, less current portion |
14,733,000 | 3,440,000 | ||||||
|
Long-term finance leases, less current portion |
- | 2,974,000 | ||||||
|
Deferred revenue, less current portion |
158,000 | 210,000 | ||||||
|
Deferred income taxes |
372,000 | 418,000 | ||||||
|
Shareholders' equity: |
||||||||
|
Common stock, no par value (10,000,000 authorized; 5,868,000 and 5,791,000 shares issued and outstanding at September 30, 2021 and at December 31, 2020 |
10,758,000 | 10,753,000 | ||||||
|
Additional paid-in capital |
7,336,000 | 7,024,000 | ||||||
|
Retained earnings |
1,472,000 | 1,497,000 | ||||||
|
Total equity-American Shared Hospital Services |
19,566,000 | 19,274,000 | ||||||
|
Non-controlling interests in subsidiaries |
4,387,000 | 4,376,000 | ||||||
|
Total shareholders' equity |
23,953,000 | 23,650,000 | ||||||
|
Total liabilities and shareholders' equity |
$ | 44,147,000 | $ | 43,653,000 | ||||
See accompanying notes
AMERICAN SHARED HOSPITAL SERVICES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2021 |
2020 |
2021 |
2020 |
|||||||||||||
|
Revenues |
$ | 4,099,000 | $ | 4,670,000 | $ | 12,939,000 | $ | 13,229,000 | ||||||||
|
Costs of revenue: |
||||||||||||||||
|
Maintenance and supplies |
561,000 | 562,000 | 1,884,000 | 1,748,000 | ||||||||||||
|
Depreciation and amortization |
1,224,000 | 1,819,000 | 3,666,000 | 5,103,000 | ||||||||||||
|
Other direct operating costs |
847,000 | 1,151,000 | 2,881,000 | 2,939,000 | ||||||||||||
| 2,632,000 | 3,532,000 | 8,431,000 | 9,790,000 | |||||||||||||
|
Gross margin |
1,467,000 | 1,138,000 | 4,508,000 | 3,439,000 | ||||||||||||
|
Selling and administrative expense |
1,119,000 | 1,135,000 | 3,293,000 | 3,556,000 | ||||||||||||
|
Interest expense |
162,000 | 254,000 | 587,000 | 803,000 | ||||||||||||
|
Operating income (loss) |
186,000 | (251,000 | ) | 628,000 | (920,000 | ) | ||||||||||
|
(Loss) on extinguishment of debt |
- | - | (401,000 | ) | - | |||||||||||
|
Interest and other (loss) income |
(1,000 | ) | 3,000 | - | 7,000 | |||||||||||
|
Income (loss) before income taxes |
185,000 | (248,000 | ) | 227,000 | (913,000 | ) | ||||||||||
|
Income tax expense (benefit) |
17,000 | (34,000 | ) | (1,000 | ) | (192,000 | ) | |||||||||
|
Net income (loss) |
168,000 | (214,000 | ) | 228,000 | (721,000 | ) | ||||||||||
|
Less: Net (income) loss attributable to non-controlling interest |
(135,000 | ) | 5,000 | (253,000 | ) | (106,000 | ) | |||||||||
|
Net income (loss) attributable to American Shared Hospital Services |
$ | 33,000 | $ | (209,000 | ) | $ | (25,000 | ) | $ | (827,000 | ) | |||||
|
Net income (loss) per share: |
||||||||||||||||
|
Income (loss) per common share - basic |
$ | 0.01 | $ | (0.03 | ) | $ | (0.00 | ) | $ | (0.14 | ) | |||||
|
Income (loss) per common share - diluted |
$ | 0.01 | $ | (0.03 | ) | $ | (0.00 | ) | $ | (0.14 | ) | |||||
See accompanying notes
AMERICAN SHARED HOSPITAL SERVICES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
(Unaudited)
|
FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020 |
||||||||||||||||||||||||||||
| Common Shares | Common Stock | Additional Paid-in Capital |
Retained Earnings |
Sub-Total ASHS |
Non-controlling Interests in Subsidiaries |
Total |
||||||||||||||||||||||
|
Balances at January 1, 2020 |
5,817,000 | $ | 10,753,000 | $ | 6,725,000 | $ | 8,555,000 | $ | 26,033,000 | $ | 5,778,000 | $ | 31,811,000 | |||||||||||||||
|
Stock-based compensation expense |
- | - | 56,000 | - | 56,000 | - | 56,000 | |||||||||||||||||||||
|
Restricted common shares returned to the plan |
(129,000 | ) | - | - | - | - | - | - | ||||||||||||||||||||
|
Cash distributions to non-controlling interests |
- | - | - | - | - | (326,000 | ) | (326,000 | ) | |||||||||||||||||||
|
Net (loss) income |
- | - | - | (135,000 | ) | (135,000 | ) | 67,000 | (68,000 | ) | ||||||||||||||||||
|
Balances at March 31, 2020 |
5,688,000 | 10,753,000 | 6,781,000 | 8,420,000 | 25,954,000 | 5,519,000 | 31,473,000 | |||||||||||||||||||||
|
Stock-based compensation expense |
3,000 | - | 53,000 | - | 53,000 | - | 53,000 | |||||||||||||||||||||
|
Cash distributions to non-controlling interests |
- | - | - | - | - | (114,000 | ) | (114,000 | ) | |||||||||||||||||||
|
Net (loss) income |
- | - | - | (483,000 | ) | (483,000 | ) | 44,000 | (439,000 | ) | ||||||||||||||||||
|
Balances at June 30, 2020 |
5,691,000 | 10,753,000 | 6,834,000 | 7,937,000 | 25,524,000 | 5,449,000 | 30,973,000 | |||||||||||||||||||||
|
Stock-based compensation expense |
60,000 | - | 80,000 | - | 80,000 | - | 80,000 | |||||||||||||||||||||
|
Cash distributions to non-controlling interests |
- | - | - | - | - | (142,000 | ) | (142,000 | ) | |||||||||||||||||||
|
NCI Investment in Acquisition |
- | - | - | - | - | 17,000 | 17,000 | |||||||||||||||||||||
|
Net income |
- | - | - | (209,000 | ) | (209,000 | ) | (5,000 | ) | (214,000 | ) | |||||||||||||||||
|
Balances at September 30, 2020 |
5,751,000 | $ | 10,753,000 | $ | 6,914,000 | $ | 7,728,000 | $ | 25,395,000 | $ | 5,319,000 | $ | 30,714,000 | |||||||||||||||
|
Balances at January 1, 2021 |
5,791,000 | $ | 10,753,000 | $ | 7,024,000 | $ | 1,497,000 | $ | 19,274,000 | $ | 4,376,000 | $ | 23,650,000 | |||||||||||||||
|
Stock-based compensation expense |
10,000 | - | 107,000 | - | 107,000 | - | 107,000 | |||||||||||||||||||||
|
Net income |
- | - | - | 29,000 | 29,000 | 58,000 | 87,000 | |||||||||||||||||||||
|
Balances at March 31, 2021 |
5,801,000 | 10,753,000 | 7,131,000 | 1,526,000 | 19,410,000 | 4,434,000 | 23,844,000 | |||||||||||||||||||||
|
Stock-based compensation expense |
62,000 | - | 96,000 | - | 96,000 | - | 96,000 | |||||||||||||||||||||
|
Options exercised |
5,000 | 5,000 | - | - | 5,000 | - | 5,000 | |||||||||||||||||||||
|
Cash distributions to non-controlling interests |
- | - | - | - | - | (204,000 | ) | (204,000 | ) | |||||||||||||||||||
|
Net (loss) income |
- | - | - | (87,000 | ) | (87,000 | ) | 60,000 | (27,000 | ) | ||||||||||||||||||
|
Balances at June 30, 2021 |
5,868,000 | 10,758,000 | 7,227,000 | 1,439,000 | 19,424,000 | 4,290,000 | 23,714,000 | |||||||||||||||||||||
|
Stock-based compensation expense |
- | - | 109,000 | - | 109,000 | - | 109,000 | |||||||||||||||||||||
|
Cash distributions to non-controlling interests |
- | - | - | - | - | (38,000 | ) | (38,000 | ) | |||||||||||||||||||
|
Net income |
- | - | - | 33,000 | 33,000 | 135,000 | 168,000 | |||||||||||||||||||||
|
Balances at September 30, 2021 |
5,868,000 | $ | 10,758,000 | $ | 7,336,000 | $ | 1,472,000 | $ | 19,566,000 | $ | 4,387,000 | $ | 23,953,000 | |||||||||||||||
See accompanying notes
AMERICAN SHARED HOSPITAL SERVICES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
Nine Months Ended September 30, |
||||||||
|
2021 |
2020 |
|||||||
|
Operating activities: |
||||||||
|
Net income (loss) |
$ | 228,000 | $ | (721,000 | ) | |||
|
Adjustments to reconcile net income (loss) to net cash from operating activities (excluding assets acquired and liabilities assumed): |
||||||||
|
Depreciation and amortization |
3,750,000 | 5,209,000 | ||||||
|
Amortization of debt issuance costs |
39,000 | - | ||||||
|
Loss on extinguishment of debt |
401,000 | - | ||||||
|
Non cash lease expense |
226,000 | 215,000 | ||||||
|
Deferred income taxes |
(46,000 | ) | (192,000 | ) | ||||
|
Stock-based compensation expense |
312,000 | 189,000 | ||||||
|
Interest expense associated with lease liabilities |
32,000 | 52,000 | ||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Receivables |
(529,000 | ) | 2,242,000 | |||||
|
Prepaid expenses and other assets |
39,000 | 687,000 | ||||||
|
Asset retirement obligations |
(618,000 | ) | - | |||||
|
Accounts payable, accrued liabilities and deferred revenue |
(222,000 | ) | 784,000 | |||||
|
Income taxes |
(211,000 | ) | (141,000 | ) | ||||
|
Lease liabilities |
(258,000 | ) | (267,000 | ) | ||||
|
Net cash provided by operating activities |
3,143,000 | 8,057,000 | ||||||
|
Investing activities: |
||||||||
|
Payment for purchase of property and equipment |
(347,000 | ) | (328,000 | ) | ||||
|
Payment for acquisition, net of cash acquired |
- | (2,084,000 | ) | |||||
|
Proceeds from sale of equipment |
- | 150,000 | ||||||
|
Net cash used in investing activities |
(347,000 | ) | (2,262,000 | ) | ||||
|
Financing activities: |
||||||||
|
Principal payments on long-term debt |
(3,497,000 | ) | (1,386,000 | ) | ||||
|
Principal payments on finance leases |
(8,919,000 | ) | (2,559,000 | ) | ||||
|
Principal payments on short-term financing |
(471,000 | ) | (459,000 | ) | ||||
|
Distributions to non-controlling interests |
(242,000 | ) | (582,000 | ) | ||||
|
Proceeds from long-term debt financing, net of property and equipment acquired |
13,897,000 | - | ||||||
|
Proceeds from financing for acquisition |
- | 1,425,000 | ||||||
|
Prepayment penalties |
(401,000 | ) | - | |||||
|
Debt issuance costs long-term debt |
(325,000 | ) | (30,000 | ) | ||||
|
Proceeds from options exercised |
5,000 | - | ||||||
|
Net cash provided by (used in) financing activities |
47,000 | (3,591,000 | ) | |||||
|
Net change in cash, cash equivalents, and restricted cash |
2,843,000 | 2,204,000 | ||||||
|
Cash, cash equivalents, and restricted cash at beginning of period |
4,325,000 | 1,779,000 | ||||||
|
Cash, cash equivalents, and restricted cash at end of period |
$ | 7,168,000 | $ | 3,983,000 | ||||
|
Supplemental cash flow disclosure: |
||||||||
|
Cash paid during the period for: |
||||||||
|
Interest |
$ | 587,000 | $ | 803,000 | ||||
|
Income taxes paid |
$ | 597,000 | $ | 335,000 | ||||
|
Schedule of non-cash investing and financing activities |
||||||||
|
Lease reassessment right of use assets and lease liabilities |
$ | - | $ | 67,000 | ||||
|
Right of use assets and lease liabilities |
$ | - | $ | 135,000 | ||||
|
Interest capitalized to property and equipment |
$ | - | $ | 97,000 | ||||
|
Acquisition of equipment with long-term debt financing |
$ | 1,103,000 | $ | 1,184,000 | ||||
|
Acquisition of equipment with finance leases |
$ | - | $ | 369,000 | ||||
|
Acquisition of insurance with short-term financing |
$ | - | $ | 45,000 | ||||
|
First working capital payment related to acquisition, withholding taxes |
$ | - | $ | 43,000 | ||||
|
Estimated subsequent working capital payment for acquisition |
$ | - | $ | 354,000 | ||||
See accompanying notes
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Basis of Presentation
In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for the fair presentation of American Shared Hospital Services’ consolidated financial position as of September 30, 2021, the results of its operations for the three and nine-month periods ended September 30, 2021 and 2020, and the cash flows for the three and nine-month periods ended September 30, 2021 and 2020. The results of operations for the three and nine-months ended September 30, 2021 are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2020 have been derived from audited consolidated financial statements.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020 included in American Shared Hospital Services’ Annual Report on Form 10-K filed with the Securities and Exchange Commission.
These condensed consolidated financial statements include the accounts of American Shared Hospital Services and its subsidiaries (the “Company”) as follows: the Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), and OR21, Inc.; the Company is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and HoldCo GKC S.A. (“HoldCo”). GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). GKF acquired Gamma Knife Center Ecuador S.A. (“GKCE”) through HoldCo in June 2020.
The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. As of September 30, 2021, GKF provides Gamma Knife units to thirteen medical centers in the United States in the states of Arkansas, California, Florida, Illinois, Indiana, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, and Texas. GKF also owns and operates single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States.
The Company formed the subsidiaries GKPeru and acquired GKCE for the purposes of expanding its business internationally; Orlando and LBE to provide PBRT equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. LBE is not expected to generate revenue within the next two years.
On June 12, 2020, GKF purchased approximately 98% of the total outstanding shares of GKCE, from GKCE’s majority shareholders (the “Acquisition”). As of September 30, 2021, the Company had acquired approximately 99.3% of the total outstanding shares of GKCE. The base purchase price for the Acquisition, including acquisition of the minority shares was approximately $2,000,000. This purchase price was paid with $575,000 in cash and a $1,425,000 loan from the United States International Development Finance Corporation (“DFC”). The purchase price was subject to certain post-closing adjustments, including adjustment for GKCE’s working capital and excess cash, totaling $883,000. The DFC loan is denominated in U.S. dollars, which is also the currency of Ecuador. See “Note 9. GKCE Acquisition” for further discussion.
All significant intercompany accounts and transactions have been eliminated in consolidation.
In 2020, the COVID-19 pandemic, the resulting recession in the United States and its follow-on effects impacted business activity across industries, including the Company’s. During 2020, due to factors related to the COVID-19 pandemic such as delays in service at medical facilities and restrictions imposed by government agencies, and the Company’s customers in response to the spread of COVID-19, the Company experienced some delays in delivering certain Gamma Knife procedures and PBRT treatments. Similarly, the Company’s ability to conduct commercial efforts with its customers were disrupted as customers turned their focus to dealing with the impact of the COVID-19 pandemic on their operations and restricted access to their sites in efforts to contain the spread of the virus. The global nature of the pandemic resulted in authorities implementing numerous measures designed to contain the virus, including travel bans and restrictions, border closures, quarantines, shelter-in-place orders, business limitations and shutdowns. The prioritization of COVID-19 treatment and containment resulted in delays in decisions by the Company’s customers and their patients, obstacles to the Company’s ability to market and deliver its services, declines in treatment volumes and adverse impacts to revenues for both Gamma Knife procedures and PBRT treatments.
In 2021, following the dissemination of the vaccine for the COVID-19 virus in the United States, there was a scale back of the safety measures put into place throughout 2020. Some of the Company’s customers still experienced some delays and restrictions in providing service, but not to the same degree that occurred during 2020. Procedure volumes for the Company’s domestic Gamma Knife business for the nine-month period ended September 30, 2021, are rebounding to pre-pandemic levels. The Company’s PBRT business continues to be impacted by COVID-19 as treatment volumes continue to lag from pre-pandemic levels. As a result of the pandemic and related governmental actions, Gamma Knife procedures and PBRT treatments, which currently make up all of the Company’s revenue, have been impacted differently at each of the Company’s various locations. However, as the COVID-19 pandemic evolves and new strains of the virus develop, additional impacts may arise which may have a material impact on the Company’s business.
Based on the guidance provided in accordance with ASC 280 Segment Reporting (“ASC 280”), the Company analyzed its subsidiaries which are all in the business of leasing radiosurgery and radiation therapy equipment to healthcare providers, and concluded there are two reportable segments, domestic and foreign. The Company provides Gamma Knife and PBRT equipment to fourteen hospitals in the United States and owns and operates two single-unit facilities in Lima, Peru and Guayaquil, Ecuador as of September 30, 2021. The Company determined two reportable segments existed due to similarities in economics of business operations and geographic location. The operating results of the two reportable segments are reviewed by the Company’s CEO and President, Chief Operating and Financial Officer, who are also deemed the Company’s Chief Operating Decision Makers. As of June 30, 2020, the Company had one reportable segment. Following the Company's acquisition of GKCE in June 2020, the Company concluded it had two reportable segments.
The revenues and profit or loss, allocations for the Company's two reportable segments as of September 30, 2021 consists of the following:
|
September 30, 2021 |
September 30, 2020 |
|||||||
|
Revenues |
||||||||
|
Domestic |
$ | 10,892,000 | $ | 910,000 | ||||
|
Foreign |
2,047,000 | 12,319,000 | ||||||
|
Total |
$ | 12,939,000 | $ | 13,229,000 | ||||
|
Profit or (loss) |
||||||||
|
Domestic |
$ | (1,000 | ) | $ | 9,000 | |||
|
Foreign |
(24,000 | ) | (836,000 | ) | ||||
|
Total |
$ | (25,000 | ) | $ | (827,000 | ) | ||
Note 2. Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife units and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where indicated. As of April 1, 2021, the Company reduced its estimate for salvage value for nine of its Gamma Knife units. The net effect of this change in estimate for the three and nine-month periods ended September 30, 2021, was a decrease in net income of approximately $114,000 or $0.02 per diluted share and $228,000 or $0.04 per diluted share, respectively. This change in estimate will also impact future periods. Salvage value is based on the estimated fair value of the equipment at the end of its useful life.
Depreciation for PBRT equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.
The following table summarizes property and equipment as of September 30, 2021 and December 31, 2020:
|
September 30, |
December 31, |
|||||||
|
2021 |
2020 |
|||||||
|
Medical equipment and facilities |
$ | 72,175,000 | $ | 75,657,000 | ||||
|
Office equipment |
606,000 | 330,000 | ||||||
|
Construction in progress |
86,000 | 170,000 | ||||||
| 72,867,000 | 76,157,000 | |||||||
|
Accumulated depreciation |
(44,605,000 | ) | (45,739,000 | ) | ||||
|
Net property and equipment |
$ | 28,262,000 | $ | 30,418,000 | ||||
As of September 30, 2021, approximately $2,809,000 of the net property and equipment balance is outside of the United States.
Note 3. Long-Term Debt Financing
On April 9, 2021 the Company entered into a five year $22,000,000 credit agreement with Fifth Third Bank, N.A. (the “Credit Agreement”). The Credit Agreement includes three loan facilities. The first facility is a $9,500,000 term loan of which $6,774,000 was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs, $1,665,000 was used to finance two Gamma Knife reloads and to pay for the unload costs for two customer contracts in the first quarter of 2021, with the remaining $1,061,000 available for future projects. The second loan facility of $5,500,000 was used to refinance the Company's PBRT finance leases and associated closing costs of $5,026,000 as well as to provide additional working capital. The third loan facility provides for a $7,000,000 revolving line of credit available for future projects and general corporate purposes. The facilities have a five-year maturity and carry a floating interest of LIBOR plus 3.0% and are collateralized by a blanket lien on substantially all of the Company's assets. On December 31, 2021, LIBOR will officially be phased out. The Company will work with Fifth Third Bank to determine an alternative base rate. The Company recorded a loss on extinguishment of debt of $401,000 during the nine-month period ended September 30, 2021, related to the prepayment penalties charged by the existing lenders. The Company capitalized debt issuance costs of $310,000 related to legal and transaction fees for the Credit Agreement during the nine-month period ended September 30, 2021.
The Company’s loan with the DFC for the acquisition of GKCE was obtained through the Company’s wholly-owned subsidiary, HoldCo and is guaranteed by GKF. As of September 30, 2021, long-term debt on the Condensed Consolidated Balance Sheets was $15,814,000.
The following are contractual maturities of long-term debt by year as of September 30, 2021 excluding debt issuance costs of $313,000:
|
Year ending December 31, |
Principal |
|||
|
2021 (excluding the nine-months ended September 30, 2021) |
$ | 242,000 | ||
|
2022 |
1,344,000 | |||
|
2023 |
1,719,000 | |||
|
2024 |
2,094,000 | |||
|
2025 |
2,469,000 | |||
|
Thereafter |
8,259,000 | |||
| $ | 16,127,000 | |||
Note 4. Finance Leases
The Company's finance lease obligations were refinanced by long-term debt on April 9, 2021. See further details on the refinancing under Note 3 - Long-Term Debt Financing.
Note 5. Leases
The Company determines if a contract is a lease at inception. Under ASC 842 Leases (“ASC 842”), the Company is a lessor of equipment to various customers. Leases that commenced prior to ASC 842 adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. All of the Company’s lessor arrangements entered into after ASC 842 adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do not contain the option to terminate early or purchase the asset at the end of the term.
The Company’s Gamma Knife and PBRT contracts with hospitals are classified as operating leases under ASC 842. The related equipment is included in medical equipment and facilities on the Company’s condensed consolidated balance sheets. As all income from the Company’s lessor arrangements is solely based on procedure volume, all income is considered variable payments not dependent on an index or a rate. As such, the Company does not measure future operating lease receivables.
The Company’s lessee operating leases are accounted for as right-of-use (“ROU”) assets, other current liabilities, and lease liabilities on the condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s operating lease contracts do not provide an implicit rate for calculating the present value of future lease payments. The Company determined its incremental borrowing rate, to be in the range of approximately 4.0% and 6.0%, by using available market rates and expected lease terms. The operating lease ROU assets and liabilities also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company’s lessee operating lease agreements are for administrative office space and related equipment, and the agreement to lease clinic space for its stand-alone facility in Lima, Peru. These leases have remaining lease terms between 2 and 3 years, some of which include options to renew or extend the lease. As of September 30, 2021, operating ROU assets and liabilities were $660,000.
The following table summarizes maturities of lessee operating lease liabilities as of September 30, 2021:
|
Year ending December 31, |
Operating Leases |
|||
|
2021 (excluding the nine-months ended September 30, 2021) |
$ | 89,000 | ||
|
2022 |
353,000 | |||
|
2023 |
248,000 | |||
|
2024 |
8,000 | |||
|
Total lease payments |
698,000 | |||
|
Less imputed interest |
(38,000 | ) | ||
|
Total |
$ | 660,000 | ||
Note 6. Per Share Amounts
Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. Based on the guidance provided in accordance with ASC 260 Earnings Per Share (“ASC 260”), potentially dilutive common stock equivalents, such as diluted stock options, are not considered when their inclusion in reporting earnings per share would be dilutive to reported losses incurred per share. Because the Company reported a loss for the nine-month period ended September 30, 2021 and the three and nine-month periods ended September 30, 2020 the potentially dilutive effects of approximately 48,000 of the Company’s stock options and 13,000 of the Company’s unvested restricted stock awards for the nine-month period ended September 30, 2021, and 10,000 of the Company’s stock options and 31,000 of the Company’s unvested restricted stock awards, respectively, were not considered for the three and nine-month periods ended September 30, 2020. The computation for the three-month period ended September 30, 2021 excluded approximately 346,000 of the Company’s stock options because the exercise price of the options was higher than the average market price during the period.
The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September 30, 2021 and 2020:
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2021 |
2020 |
2021 |
2020 |
|||||||||||||
|
Net income (loss) attributable to American Shared Hospital Services |
$ | 33,000 | $ | (209,000 | ) | $ | (25,000 | ) | $ | (827,000 | ) | |||||
|
Weighted average common shares for basic earnings per share |
6,103,000 | 6,049,000 | 5,824,000 | 6,060,000 | ||||||||||||
|
Diluted effect of stock options and restricted stock awards |
20,000 | - | - | - | ||||||||||||
|
Weighted average common shares for diluted earnings per share |
6,123,000 | 6,049,000 | 5,824,000 | 6,060,000 | ||||||||||||
|
Basic earnings (loss) per share |
$ | 0.01 | $ | (0.03 | ) | $ | (0.00 | ) | $ | (0.14 | ) | |||||
|
Diluted earnings (loss) per share |
$ | 0.01 | $ | (0.03 | ) | $ | (0.00 | ) | $ | (0.14 | ) | |||||
Note 7. Stock-based Compensation
In June 2021, the Company’s shareholders approved an amendment and restatement of the Company’s Incentive Compensation Plan (the “Plan”), that among other things, increases the number of shares of the Company’s common stock reserved for issuance under the Plan to 2,580,000 and extends the term of the Plan by five years to February 22, 2027. The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. No further grants or share issuances will be made under the previous plans.
Stock-based compensation expense associated with the Company’s stock options to employees is calculated using the Black-Scholes valuation model. The Company’s stock awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is expensed over the period during which an employee is required to provide service in exchange for the award (requisite service period), usually the vesting period. Accordingly, stock-based compensation cost before income tax effect for the Company’s options and restricted stock awards in the amount of $109,000 and $312,000 is reflected in net income (loss) for the three and nine-month periods ended September 30, 2021, compared to $80,000 and $189,000 in the same periods of the prior year, respectively. At September 30, 2021, there was approximately $11,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a period of approximately four years.
On January 4, 2017, the Company entered into a Performance Share Award Agreement with three executive officers of the Company (the “Award Agreements”) for 161,766 restricted stock awards which vest upon the achievement of certain performance metrics. The Award Agreements expired on March 31, 2020. Based on the guidance in ASC 718 Stock Compensation (“ASC 718”), the Company concluded these were performance-based awards with vesting criteria tied to performance metrics. As of December 31, 2017, the Company achieved one of those certain performance metrics under the Award Agreements and recognized stock compensation expense of approximately $108,000 related to these awards. The unrecognized stock-based compensation expense for these awards was approximately $434,000 and the unvested awards of approximately 129,000 shares were returned to the Plan as of March 31, 2020.
The following table summarizes stock option activity for the nine-month periods ended September 30, 2021 and 2020:
|
Stock Options |
Grant Date Weighted- Average Exercise Price |
Weighted- Average Remaining Contractual Life (in Years) |
Intrinsic Value |
|||||||||||||
|
Outstanding at January 1, 2021 |
417,000 | $ | 2.79 | 1.61 | $ | 2,000 | ||||||||||
|
Granted |
6,000 | $ | 2.92 | 7.00 | $ | - | ||||||||||
|
Exercised |
(22,000 | ) | $ | 2.65 | - | $ | - | |||||||||
|
Forfeited |
(7,000 | ) | $ | 2.51 | - | $ | - | |||||||||
|
Outstanding at September 30, 2021 |
394,000 | $ | 2.80 | 0.90 | $ | 17,000 | ||||||||||
|
Exercisable at September 30, 2021 |
383,000 | $ | 2.80 | 0.77 | $ | - | ||||||||||
|
Outstanding at January 1, 2020 |
450,000 | $ | 2.78 | 2.44 | $ | 27,000 | ||||||||||
|
Granted |
10,000 | $ | 1.88 | 7.00 | $ | - | ||||||||||
|
Forfeited |
(40,000 | ) | $ | 2.58 | - | $ | - | |||||||||
|
Outstanding at September 30, 2020 |
420,000 | $ | 2.78 | 1.86 | $ | - | ||||||||||
|
Exercisable at September 30, 2020 |
403,000 | $ | 2.80 | 1.69 | $ | - | ||||||||||
Note 8. Income Taxes
The Company generally calculates its effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, the Company computes its provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. The Company’s effective income tax rate is highly influenced by relative income or losses reported and the amount of the nondeductible stock-based compensation associated with grants of its common stock options and from the results of foreign operations. A small change in estimated annual pretax income (loss) can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, the Company has computed its provision for income taxes for the three and nine-month periods ended September 30, 2021 and 2020 by applying the actual effective tax rates to income or (loss) reported within the condensed consolidated financial statements through those periods.
Note 9. GKCE Acquisition
On June 18, 2019, the Company entered into a Stock Purchase Agreement (the “Agreement”) to acquire Gamma Knife Center Ecuador S.A. (“GKCE”) from GKCE’s selling majority shareholders. GKCE is a well-established Gamma Knife operation founded in 2009 as a private clinic to introduce advanced stereotactic radiosurgery into Ecuador and continues to operate the only Gamma Knife unit in the country. The Company acquired GKCE for the continued expansion of its business internationally.
The Acquisition has been accounted for according to ASC 805 Business Combinations (“ASC 805”) using the acquisition method of accounting. Under the acquisition method of accounting, all assets acquired, including goodwill and other intangible assets, should be stated at fair value at the time of acquisition. The measurement period for the acquisition of GKCE ended June 12, 2021. As of June 30, 2021, the allocation of purchase price consideration and the Company's analysis of fair value of certain tangible, intangible assets, and residual goodwill was complete. As of June 30, 2021, accounting for the Closing Date accounts receivable balances, allowance on the uncollected accounts receivable balances, and related liabilities, was complete.
The following table summarizes the fair value of assets acquired and liabilities assumed at the date of acquisition:
|
June 12, 2020 |
||||
|
Cash and cash equivalents |
$ | 432,000 | ||
|
Accounts receivable |
854,000 | |||
|
Prepaid expense and other |
22,000 | |||
|
Building |
385,000 | |||
|
Land |
19,000 | |||
|
Medical equipment |
319,000 | |||
|
Purchased intangible assets |
78,000 | |||
|
Goodwill |
1,265,000 | |||
|
Total assets acquired |
$ | 3,374,000 | ||
|
Accounts payable |
$ | (193,000 | ) | |
|
Income taxes payable |
(141,000 | ) | ||
|
Deferred income taxes |
(66,000 | ) | ||
|
Employee compensation and benefits |
(91,000 | ) | ||
|
Total liabilities assumed |
(491,000 | ) | ||
|
Consideration allocated to assets acquired and liabilities assumed |
$ | 2,883,000 | ||
|
First working capital payment |
$ | (515,000 | ) | |
|
Estimated subsequent working capital payment |
(368,000 | ) | ||
|
Base purchase consideration |
$ | 2,000,000 | ||
The Company has allocated the purchase price of GKCE to the tangible assets, liabilities, and intangible asset acquired, based on their estimated fair values. Goodwill represents the excess of the purchase price consideration over the fair value of the identifiable tangible and intangible assets assumed. The Company believes the amount of goodwill resulting from the acquisition is primarily attributable to expected synergies from an assembled and trained workforce and enhanced opportunities for growth and innovation. The goodwill resulting from the acquisition is not tax deductible.
The following table summarizes the fair value of the tangible assets acquired at the date of acquisition:
|
Fair Value |
Useful Life (in Years) |
||||
|
Building |
$ | 385,000 |
20 |
||
|
Land |
19,000 | ||||
|
Medical equipment |
302,000 |
2 |
|||
|
Other fixed assets |
17,000 |
2 |
|||
|
Total tangible assets |
$ | 723,000 | |||
The Company also acquired intangible assets with a fair value of $78,000. The intangible asset identified was GKCE's trade name and the Company assigned an indefinite useful life
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This quarterly report to the Securities and Exchange Commission may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued treatment growth of the Company’s MEVION S250 system, the expansion of the Company’s PBRT business, the timing and expansion of treatments by new Gamma Knife systems, the Company's expansion into new markets and the Company’s acquisitions and potential market segments for its services, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s PBRT business, the risks of the COVID-19 pandemic and its effect on the Company’s business operations and financial condition, the risk of expanding within or into new markets, and the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company's financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and the definitive Proxy Statement for the Annual Meeting of Shareholders held on June 25, 2021.
The Company recognizes revenues under ASC 842 and ASC 606 Revenue from Contracts with Customers (“ASC 606”). The Company had thirteen Gamma Knife units and one PBRT system, and fifteen Gamma Knife units and one PBRT system in operation in the United States as of September 30, 2021 and 2020, respectively. Six of the Company’s thirteen current Gamma Knife customers are under fee-per-use contracts, and seven customers are under retail arrangements. The Company, through GKF, also owns and operates two single-unit, international Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. These two units economically function similarly to the Company’s turn-key retail arrangements. The Company’s PBRT system at Orlando Health – UF Health Cancer Center (“Orlando Health”) is also considered a retail arrangement.
Rental income from medical services – The Company recognizes revenues under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s contracts are typically for a ten-year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing. Revenues from fee per use contracts is determined by each hospital’s contracted rate. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Under turn-key arrangements, the Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the equipment. Operating costs are determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. For turn-key sites, the Company also shares a percentage of net operating profit. The Company records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The operating costs and estimated net operating profit are recorded as other direct operating costs in the condensed consolidated statement of operations. For the three and nine-month periods ended September 30, 2021 the Company recognized revenues of approximately $3,477,000 and $10,892,000 compared to $4,215,000 and $12,319,000 for the same periods in the prior year, respectively, under ASC 842.
Patient income – The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru’s payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid approximately 30 to 60 days upon invoice. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. Accounts receivable earned by GKPeru and GKCE were not significant for thethree and nine-month periods ended September 30, 2021 and 2020. For the three and nine-month periods ended September 30, 2021 the Company recognized revenues of approximately $622,000 and $2,047,000 compared to $455,000 and $910,000 for the same periods in the prior year, respectively, under ASC 606.
The Centers for Medicare and Medicaid (“CMS”) have established a 2022 delivery code reimbursement rate of approximately $7,943 ($7,773 in 2021) for a Medicare Gamma Knife treatment. The approximate CMS reimbursement rates for delivery of PBRT for a simple treatment without compensation for 2022 is $554 ($543 in 2021) and $1,321 ($1,298 in 2021) for simple with compensation, intermediate and complex treatments, respectively.
On September 18, 2020, CMS issued the final rule that would implement a new mandatory payment model for radiation oncology services: the RO APM. The RO APM is scheduled to commence January 1, 2022 and will be in effect for a five (5) year period. The RO APM significantly alters CMS' payment methodology from a fee for service paradigm to a set reimbursement by cancer type methodology for radiation services provided within a 90 day episode of care. Under the RO APM, hospital based and free-standing radiation therapy providers are mandatorily required to participate in the model based on whether the radiation therapy provider is located within a randomly selected Core Based Statistical Area (“CBSA”). CMS projects that providers treating approximately 30% of radiation oncology patients have been selected to participate in the RO APM. The remaining providers not included in the RO APM will continue to receive reimbursement based on a fee-for-service methodology. The RO APM includes but is not limited to PBRT and Gamma Knife services. Four (4) of the Company's Gamma Knife centers are scheduled to be included in the RO APM. It is not anticipated that inclusion in the RO APM will have a significant impact on the Company's Gamma Knife revenues. The Company's PBRT center was not selected for inclusion in the RO APM. For centers not included in the RO APM proposed model, Medicare reimbursement in 2021 for the most commonly used PBRT delivery codes increases by approximately 4.1% and decreases by approximately 1.7% for Gamma Knife.
In 2020, the COVID-19 pandemic, the resulting recession in the United States and its follow-on effects impacted business activity across industries, including the Company’s. During 2020, due to factors related to the COVID-19 pandemic such as delays in service at medical facilities and restrictions imposed by government agencies, and the Company’s customers in response to the spread of COVID-19, the Company experienced some delays in delivering certain Gamma Knife procedures and PBRT treatments. Similarly, the Company’s ability to conduct commercial efforts with its customers were disrupted as customers turned their focus to dealing with the impact of the COVID-19 pandemic on their operations and restricted access to their sites in efforts to contain the spread of the virus. The global nature of the pandemic resulted in authorities implementing numerous measures designed to contain the virus, including travel bans and restrictions, border closures, quarantines, shelter-in-place orders, business limitations and shutdowns. The prioritization of COVID-19 treatment and containment resulted in delays in decisions by the Company’s customers and their patients, obstacles to the Company’s ability to market and deliver its services, declines in treatment volumes and adverse impacts to revenues for both Gamma Knife procedures and PBRT treatments.
In 2021, following the dissemination of the vaccine for the COVID-19 virus in the United States, there was a scale back of the safety measures put into place throughout 2020. Some of the Company’s customers still experienced some delays and restrictions in providing service, but not to the same degree that occurred during 2020. Procedure volumes for the Company’s domestic Gamma Knife business for the nine-month period ended September 30, 2021, are rebounding to pre-pandemic levels. The Company’s PBRT business continues to be impacted by COVID-19 as treatment volumes continue to lag from pre-pandemic levels. As a result of the pandemic and related governmental actions, Gamma Knife procedures and PBRT treatments, which currently make up all of the Company’s revenue, have been impacted differently at each of the Company’s various locations. However, as the COVID-19 pandemic evolves and new strains of the virus develop, additional impacts may arise which may have a material impact on the Company’s business. However, as the COVID-19 pandemic evolves and new strains of the virus develop, additional impacts may arise which may have a material impact on the Company’s business.
The impact of the COVID-19 pandemic for the three and nine-month periods ended September 30, 2021 and 2020 has varied by location based on the stage of containment and actions by government agencies. The impact on treatments and costs in the three and nine-month periods ended September 30, 2021 and 2020 did not appear material for the Gamma Knife. The COVID-19 pandemic appears to have had a greater impact on PBRT fractions for the three and nine-month periods ended September 30, 2021 and 2020.
Revenues decreased by $571,000 and $290,000 to$4,099,000 and $12,939,000, for the three and nine-month periods ended September 30, 2021 compared to $4,670,000 and $13,229,000 for the same periods in the prior year, respectively.
Revenues generated from the Company’s PBRT system decreased by $394,000 and $392,000 to $1,293,000 and $4,372,000 for the three and nine-month periods ended September 30, 2021 compared to $1,687,000 and $4,764,000 for the same periods in the prior year, respectively. The decrease in PBRT revenues for the three and nine-month periods ended September 30, 2021 was due to lower volumes offset by a higher average reimbursement for the periods.
The number of PBRT fractions decreased by 659 and 1,346 to 973 and 3,313 for the three and nine-month periods ended September 30, 2021 compared to 1,632 and 4,659 for the same periods in the prior year, respectively. The decrease in PBRT volume for the three and nine-month periods ended September 30, 2021 was primarily due to the continued impact from the COVID-19 pandemic and down-time for repair of system components during the nine-month period ended September 30, 2021.
Gamma Knife revenues decreased $177,000 and increased $161,000 to $2,806,000 and $8,626,000 for the three and nine-month periods ended September 30, 2021 compared to $2,983,000 and $8,465,000 for the same periods in the prior year, respectively. For the three-month period ended September 30, 2021, the decrease in Gamma Knife revenue was due to an decrease in procedures, offset by an increase in average reimbursement. The increase in average reimbursement was driven by the expiration of a contract that expired in the fourth quarter of 2020, which was reimbursed at a lower rate, and an increase in the average rate at the Company’s retail sites. For the nine-month period ended September 30, 2021, the increase in Gamma Knife revenue was due an increase in average reimbursement, offset by a decrease in procedures. This increase was due to higher reimbursement at the Company’s retail sites, driven by several large reimbursements from commercial payors, offset by the expiration of a contract that expired in the fourth quarter of 2020, which was reimbursed at a lower rate.
The number of Gamma Knife procedures decreased by 41 and 36 to 336 and 1,067 for the three and nine-month periods ended September 30, 2021 compared to 377 and 1,103 for the same periods in the prior year, respectively. The decrease in Gamma Knife procedures for the three and nine-month periods ended September 30, 2021 was primarily due to the expiration of one contract in the fourth quarter of 2020 and another contract in the first quarter of 2021, offset by the acquisition of GKCE in June 2020. Excluding the two Gamma Knife contracts that expired for the three and nine-month periods ended September 30, 2021, and the impact from GKCE’s procedures for the nine-month period ended September 30, 2021, Gamma Knife procedures for existing customer sites increased by 35 and 79 for the three and nine-month periods ended September 30, 2021 compared to the same periods of the prior year.
The Company’s contract for IGRT equipment and related equipment services expired in April 2020. As of March 31, 2021, the Company reviewed its estimate of related revenues and accounts receivable and determined the amount should be $0 and wrote off the balance of $59,000.
Total costs of revenue decreased by $900,000 and $1,359,000 to $2,632,000 and $8,431,000 for the three and nine-month periods ended September 30, 2021 compared to $3,532,000 and $9,790,000 for the same periods in the prior year, respectively.
Maintenance and supplies decreased by $1,000 and increased by $136,000 to $561,000 and $1,884,000 for the three and nine-month periods ended September 30, 2021 compared to $562,000 and $1,748,000 for the same periods in the prior year, respectively. The increase in maintenance and supplies for the nine-month period ended September 30, 2021 was primarily due to a maintenance contract for one of the Company’s Gamma Knife Icon upgrades which commenced in the fourth quarter of 2020.
Depreciation and amortization decreased by $595,000 and $1,437,000 to $1,224,000 and $3,666,000 for the three and nine-month periods ended September 30, 2021 compared to $1,819,000 and $5,103,000 for the same periods in the prior year, respectively. The decrease in depreciation and amortization for the three and nine-month periods ended September 30, 2021 was primarily due to the expiration of one contract in the fourth quarter of 2020 and another contract in the first quarter of 2021. In addition, the Company determined some of its Gamma Knife equipment was impaired as of December, 31, 2020 and the related equipment values were written off. Therefore, there was no depreciation expense incurred on this equipment for the three and nine-month periods ended September 30, 2021. These decreases were offset by a change in estimate for salvage value for nine of the Company’s Gamma Knife units implemented in the second quarter of 2021. The net effect of this change in estimate for the three and nine-month periods ended September 30, 2021, was a decrease in net income of approximately $114,000 or $0.02 per diluted share and $228,000 or $0.04 per diluted share, respectively. Salvage value is based on the estimated fair value of the equipment at the end of its useful life. This change in estimate also impacts future periods.
Other direct operating costs decreased by $304,000 and $58,000 to $847,000 and $2,881,000 for the three and nine-month periods ended September 30, 2021 compared to $1,151,000 and $2,939,000 for the same periods in the prior year, respectively. The decrease in other direct operating costs for the three and nine-month periods ended September 30, 2021 was primarily due to the expiration of one contract in the first quarter of 2021 and a decrease in operating costs for the Company’s existing retail sites.
Selling and administrative costs decreased by $16,000 and $263,000 to $1,119,000 and $3,293,000 for the three and nine-month periods ended September 30, 2021 compared to $1,135,000 and $3,556,000 for the same periods in the prior year, respectively. The decrease for the three-month period ended September 30, 2021 was due to legal, accounting and tax fees. The decrease for the nine-month period ended September 30, 2021, was due to legal and accounting fees, and, tax, legal and other consulting fees related the Company’s acquisition of GKCE incurred in the prior year.
Interest expense decreased by $92,000 and $216,000 to $162,000 and $587,000 for the three and nine-month periods ended September 30, 2021 compared to $254,000 and $803,000 for the same periods in the prior year, respectively. On April 9, 2021, the Company refinanced predominantly all of its existing debt and finance lease portfolio at a lower effective interest rate compared to the Company's historic portfolio rate, reducing interest expense.
Interest and other income was a loss of $1,000 and $0 for the three and nine-month periods ended September 30, 2021 compared to income of $3,000 and $7,000 for the same periods in the prior year, respectively. Interest and other income is comprised of interest expense and interest earned.
The Company recorded a loss on the extinguishment of debt of $401,000 for the nine-month period ended September 30, 2021 On April 9, 2021, the Company refinanced the majority of its existing debt and finance lease portfolio with a new lender. The prepayment penalties charged by the existing lenders of $401,000 was recorded as a loss on extinguishment during the three-month period ended June 30, 2021.
Income tax expense increased by $51,000 and $191,000 to $17,000 and a benefit of $1,000 for the three and nine-month periods ended September 30, 2021 compared to an income tax benefit of $34,000 and $192,000 for the same periods in the prior year, respectively. The increase in income tax expense for the three and nine-month periods ended September 30, 2021 was due to higher taxable income attributable to GKF and the acquisition of GKCE.
Net income attributable to non-controlling interest increased by $140,000 and $147,000 to $135,000 and $253,000 for the three and nine-month periods ended September 30, 2021 compared to a net loss of $5,000 and net income of $106,000 for the same periods in the prior year, respectively. Net income attributable to non-controlling interests represents net income earned by the 19% non-controlling interest in GKF, and net income of the non-controlling interests in various subsidiaries controlled by GKF. The decrease or increase in net income attributable to non-controlling interests reflects the relative profitability of GKF.
Net income increased by $242,000 and $802,000 to net income of $33,000, or $0.01 per diluted share and a net loss of $25,000 or $0.00 per diluted share for the three and nine-month periods ended September 30, 2021 compared to a net loss of $209,000, or $0.03 per diluted share and a net loss of $827,000 or $0.14 per diluted share for the same periods in the prior year, respectively. Net income for nine-month period ended September 30, 2021, excluding the loss on extinguishment of debt, net of the impact from minority interest and taxes, was $219,000 or $0.04 per diluted share. Net income increased for the three and nine-month periods ended September 30, 2021 due to a decrease in depreciation expense, operating costs, selling and administrative costs and interest expense.
Liquidity and Capital Resources
The Company had cash, cash equivalents and restricted cash of $7,168,000 at September 30, 2021 compared to $4,325,000 at December 31, 2020. The Company’s cash position increased by $2,843,000 primarily due to cash from operating activities of $3,143,000, proceeds from long-term debt financing of $13,897,000 and proceeds from options exercised of $5,000. This increase was offset by payment for the purchase of property and equipment of $347,000, payments on long-term debt and finance leases of $12,416,000, payments on short-term financing of $471,000, distributions to non-controlling interests of $242,000, prepayment penalties of $401,000 and debt issuance costs of $325,000.
The Company has scheduled interest and principal payments under its debt obligations of approximately $1,657,000 during the next 12 months. The Company believes that its cash on hand, cash flow from operations, and other cash resources are adequate to meet its scheduled debt obligations and working capital requirements during the next 12 months. See additional discussion below related to commitments.
The Company as of September 30, 2021 had shareholders’ equity of $23,953,000, working capital of $9,209,000 and total assets of $44,147,000.
Commitments
On December 20, 2018, the Company signed Second Amendments to two System Build Agreements for the Company’s second and third Mevion PBRT units. The Company and Mevion have agreed to upgrade the second and third PBRT units for which the Company has purchase commitments. The Company is actively seeking sites for these units but, to date, has not entered into agreements with any party for either placement of a PBRT unit or the related financing. The Company projects that it will be required to commence delivery of the second and third PBRT units no later than 2023. In the event the Company is unable to enter into customer agreements within the requisite time frame or receive an extension from Mevion, the Company could forfeit its deposits. As of September 30, 2021, the Company had commitments, after deposits, to purchase two MEVION S250i PBRT systems for $34,000,000.
As of September 30, 2021, the Company had commitments to perform one Cobalt-60 reload and install four Leksell Gamma Knife Icon Systems (“Icon”) at existing customer sites, and purchase two Linear Accelerator (“LINAC”) systems, one to be placed at an existing customer site and one at a new customer site. The Company also has a commitment to upgrade the Gamma Knife unit at its stand-alone facility in Ecuador to a Perfexion. The Cobalt-60 reload will be placed at an existing customer site in the fourth quarter of 2021. The Icon upgrades and LINAC purchases are scheduled to occur between 2022 and 2023. The Company expects to upgrade the equipment in Ecuador by mid-year 2022. The Company has a commitment from DFC to finance this upgrade. Total Gamma Knife and LINAC commitments as of September 30, 2021 were $10,860,000. It is the Company’s intent to finance these commitments. There are no significant cash requirements, pending financing, for these commitments in the next 12 months. There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company. However, the Company currently has cash on hand of $7,168,000 and a line of credit of $7,000,000 to fund these projects.
On July 21, 2017, the Company entered into a Maintenance and Support Agreement (the “Mevion Service Agreement”) with Mevion, which provides for maintenance and support of the Company’s PBRT unit at Orlando Health. The Mevion Service Agreement began September 5, 2017, was amended in 2018, and renews annually over a five year period. The agreement requires an annual prepayment of $1,649,000 for the current contractual period. This payment portion was recorded as a prepaid contract and will be amortized over the one-year service period.
As of September 30, 2021, the Company had commitments to service and maintain its Gamma Knife and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta and Mobius Imaging, LLC. In addition, in April 2019, the Company signed agreements to service the Icon upgrades which will be installed at various dates between 2022 and 2023. The Company’s commitments to purchase two LINAC systems also include a 9-year and 5-year agreement to service the equipment, respectively. Total service commitments as of September 30, 2021 were $8,535,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company does not hold or issue derivative instruments for trading purposes and is not a party to any instruments with leverage or prepayment features. The Company does not have affiliation with partnerships, trusts or other entities whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements, and therefore has no exposure to the financing, liquidity, market or credit risks associated with such entities. At September 30, 2021, the Company had no significant long-term, market-sensitive investments.
Item 4. Controls and Procedures
Under the supervision and with the participation of our management, including our chief executive officer and our president and chief operating and financial officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934. These controls and procedures are designed to ensure that material information relating to the company and its subsidiaries is communicated to the chief executive officer and the chief financial officer. Based on that evaluation, our chief executive officer and our chief financial officer concluded that, as of September 30, 2021, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to the chief executive officer and the chief financial officer, and recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There were no changes in our internal control over financial reporting during the three and nine-months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 1A. Risk Factors
There were no material changes during the period covered in this report to the risk factors previously disclosed in Part 1, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibit Index
|
Incorporated by reference herein |
||||||||||||||||||||||||||
|
Exhibit Number |
Description |
Form |
Exhibit |
Date |
||||||||||||||||||||||
| 10.1 | * | Fourth Amendment to Purchased Services Agreement dated as of July 28, 2021 between GK Financing, LLC and University of Southern California | ||||||||||||||||||||||||
|
* |
Certification of Chief Executive Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|||||||||||||||||||||||||
|
* |
Certification of Chief Financial Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|||||||||||||||||||||||||
|
ǂ |
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|||||||||||||||||||||||||
|
101.INS |
* |
Inline XBRL Instance Document |
||||||||||||||||||||||||
|
101.SCH |
* |
Inline XBRL Taxonomy Extension Schema Document |
||||||||||||||||||||||||
|
101.CAL |
* |
Inline XBRL Taxonomy Calculation Linkbase Document |
||||||||||||||||||||||||
|
101.DEF |
* |
Inline XBRL Taxonomy Definition Linkbase Document |
||||||||||||||||||||||||
|
101.LAB |
* |
Inline XBRL Taxonomy Label Linkbase Document |
||||||||||||||||||||||||
|
101.PRE |
* |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
||||||||||||||||||||||||
|
104 |
* |
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline Instance XBRL contained in Exhibit 101 |
||||||||||||||||||||||||
|
* |
Filed herewith. |
|||||||||||||||||||||||||
|
ǂ |
Furnished herewith. |
|||||||||||||||||||||||||
|
# |
Portions of this exhibit (indicated therein by asterisks) have been omitted for confidential treatment. |
|||||||||||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AMERICAN SHARED HOSPITAL SERVICES
Registrant
|
Date: |
November 10, 2021 |
/s/ Raymond C. Stachowiak |
||||||
|
Raymond C. Stachowiak |
||||||||
|
Chief Executive Officer |
||||||||
|
Date: |
November 10, 2021 |
/s/ Craig K. Tagawa |
||||||
|
Craig K. Tagawa |
||||||||
|
President, Chief Operating and Financial Officer |
Exhibit 10.1
FOURTH AMENDMENT TO PURCHASED SERVICES AGREEMENT
This FOURTH AMENDMENT TO PURCHASED SERVICES AGREEMENT (this “Fourth Amendment”) is dated effective as of July 28, 2021 (the "Effective Date"), and is entered into by and between GK FINANCING, LLC, a California limited liability company (“GKF”), or its wholly owned subsidiary whose obligations hereunder shall be guaranteed by GKF, and UNIVERSITY OF SOUTHERN CALIFORNIA, a California nonprofit public benefit corporation (“Hospital”).
Recitals:
A. On March 5, 2008, GKF and USC University Hospital, Inc. entered into a certain Purchased Services Agreement, which Purchased Services Agreement was (i) transferred and assigned by USC University Hospital, Inc. to Hospital pursuant to a certain letter dated effective as of March 31, 2009; and (ii) amended by a certain First Amendment to Purchased Services Agreement dated effective as of April 1, 2009 (the "First Amendment"); and (iii) amended by a Second Amendment to Purchased Services Agreement dated effective as of October 1, 2013 (the “Second Amendment”); and (iv) amended by a Third Amendment to Purchased Services Agreement dated effective as of July 30, 2021 between GKF and Hospital (as so assigned and amended, the "Agreement").
B. GKF and Hospital desire to further amend the Agreement as set forth herein.
NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which are acknowledged, the parties hereby amend the Agreement as follows:
Agreement:
1. Defined Terms. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Agreement.
2. Extension of Term.
a. It is acknowledged that pursuant to Amendment Three, but subject to Section 2.b below, the Term of the Agreement is currently set to expire on July 28, 2021.
b. The Term of the Agreement is hereby extended to the earlier of (i) July 27, 2022, or (ii) the date on which the first clinical procedure is performed on the Hospital’s new Leksell Gamma Knife Icon; provided that the Hospital gives GKF a 60 day notice of early termination. The Term of the Agreement may be further extended beyond July 27, 2022 on a month to month basis pursuant to mutual written agreement between the parties.
c. During the period from July 28, 2021 through July 27, 2022, GKF shall waive the per procedure Purchased Services Payments for up to five (5) Procedures that are performed using any equipment or devices other than the Equipment (each, an “Excluded Procedure”); provided that, if at any time or from time-to-time the foregoing limits pertaining to Excluded Procedures is exceeded by Hospital, then, GKF shall be entitled to receive Purchased Services Payments for each Procedure in excess of such limits in accordance with the amounts set forth in the Agreement.
4. No Additional Responsibilities. It is understood by the parties that GKF is not responsible for any upgrades, hardware, cobalt reloading, software changes and/or other modifications to the Equipment, except as otherwise agreed upon in writing by Hospital and GKF.
5. Miscellaneous. This Fourth Amendment may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all of which counterparts shall together constitute the same instrument. The captions and paragraph headings used herein are for convenience only and shall not be used in construing or interpreting this Fourth Amendment. This Fourth Amendment constitutes the full and complete agreement and understanding between the parties hereto concerning the subject matter hereof and shall supersede any and all prior written and oral agreements with regard to such subject matter.
6. Full Force and Effect. Except as amended by this Fourth Amendment, all of the terms and provisions of the Agreement shall remain unchanged and in full force and effect. Unless the context requires otherwise, all references in the Agreement to (i) the “Agreement” shall be deemed to mean the Agreement as amended by this Fourth Amendment, and (ii) the “Term” shall be deemed to refer to the Term, as extended pursuant to this Fourth Amendment. Notwithstanding the foregoing, to the extent of any conflict or inconsistency between the terms and provisions of this Fourth Amendment and that of the Agreement, the terms and provisions of this Fourth Amendment shall prevail and control.
IN WITNESS WHEREOF, the parties have executed this Fourth Amendment effective as of the Effective Date.
|
GKF: GK FINANCING, LLC By: _/ s / Craig K. Tagawa__________ Name: Craig K. Tagawa__________ Title: ____CEO________________ |
Hospital: UNIVERSITY OF SOUTHERN CALIFORNIA By: ___/ s / Rod Hanners__________ Name: ______Rod Hanners________ Title: __________CEO_________ |
Exhibit 31.1
CERTIFICATION
I, Raymond C. Stachowiak, as chief executive officer of American Shared Hospital Services, certify that:
1. I have reviewed this quarterly report on Form 10-Q of American Shared Hospital Services;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
/s/ Raymond C. Stachowiak
Raymond C. Stachowiak
Chief Executive Officer
Exhibit 31.2
CERTIFICATION
I, Craig K. Tagawa., as president, chief operating and financial officer of American Shared Hospital Services, certify that:
1. I have reviewed this quarterly report on Form 10-Q of American Shared Hospital Services;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
/s/ Craig K. Tagawa |
|
|
Craig K. Tagawa |
|
|
President, Chief Operating and Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of American Shared Hospital Services for the quarterly period ended September 30, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
Ray Stachowiak, the Chief Executive Officer and Craig K. Tagawa, the President, Chief Operating a Financial Officer of American Shared Hospital Services, each certifies that, to the best of his knowledge:
|
1. |
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
2. |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Shared Hospital Services. |
|
/s/ Raymond C. Stachowiak |
|
|
Raymond C. Stachowiak |
|
|
Chief Executive Officer |
|
|
/s/ Craig K. Tagawa |
|
|
Craig K. Tagawa |
|
|
President, Chief Operating and Financial Officer |